Verona Pharma plc

Equities

VRNA

US9250501064

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:22:53 28/05/2024 pm IST			5-day change	1st Jan Change
12.5 ^USD	+3.78%		-0.32%	-37.32%

05:19pm	European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading	MT
23/05	Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	MT

Verona Pharma plc Reports Earnings Results for the Third Quarter Ended September 30, 2023

November 02, 2023 at 12:34 pm IST

Verona Pharma plc reported earnings results for the third quarter ended September 30, 2023. For the third quarter, the company reported net loss was USD 14.69 million compared to USD 15.65 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.24 a year ago.

Latest news about Verona Pharma plc

European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading	08:49pm	MT
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	24/05	MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	22/05	MT
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	20/05	MT
HC Wainwright Adjusts Price Target on Verona Pharma to $30 From $32, Maintains Buy Rating	13/05	MT
Verona Pharma Signs Financing Agreements for Up to $650 Million	09/05	MT
Verona Pharma Shares Decline After Q1 Loss Widens	09/05	MT
Transcript : Verona Pharma plc, Q1 2024 Earnings Call, May 09, 2024	09/05
Verona Pharma plc Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	06/05	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	03/05	MT
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024	02/05	CI
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	22/04	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	16/04	MT
Piper Sandler Raises Verona Pharma's Price Target to $36 From $31, Keeps Overweight Rating	16/04	MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	05/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	04/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	26/03	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	25/03	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	14/03	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	13/03	MT
Verona Pharma plc Announces Management Changes	04/03	CI
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat	01/03	MT
Verona Pharma Shares Rise After Narrower-Than-Expected Q4 Loss	29/02	MT
Verona Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI

Chart Verona Pharma plc

Duration

Period

More charts

Company Profile

Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzymeâs phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.04 USD

Average target price

34.29 USD

Spread / Average Target

+184.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERONA PHARMA PLC	-37.32%	98Cr
VERTEX PHARMACEUTICALS INCORPORATED	+9.89%	12TCr
REGENERON PHARMACEUTICALS, INC.	+10.25%	11TCr
BIONTECH SE	-11.80%	2.34TCr
ARGENX SE	-1.69%	2.21TCr
GENMAB A/S	-10.23%	1.83TCr
WUXI APPTEC CO., LTD.	-41.92%	1.66TCr
BEIGENE, LTD.	-15.91%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+6.16%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+15.80%	1.17TCr

Bio Therapeutic Drugs